Applicants: Michael J. Elliott et al.

Serial No.: 08/602,272

Filed: February 16, 1996

Page 4

REMARKS

Claims 6, 9, 10, 12-15, 29, 31, 32, 34-37, 51 and 52 are pending in the subject application. By this amendment, applicants have cancelled claims 29, 31, 32, 34-36 and 52 without disclaimer or prejudice to their right to pursue the subject matter of these claims in another application, amended claim 6, and added new claim 53. Upon entry of this Amendment, claims 6, 9, 10, 12-15, 37, 51 and 53 will be pending and under examination. Applicants maintain that this amendment does not involve any issue of new matter.

Support for amended claim 6 may be found in the specification at, inter alia, page 5, line 34 through page 6, line 8; and page 7, lines 9-11 and 27-32.

Support for new claim 53 may be found in the specification at, inter alia, page 5, lines 26-31.

Applicants: Michael J. Elliott et al.

Serial No. : 08/602,272

Filed: February 16, 1996

Page 5

Rejections Under 35 U.S.C. §112, First Paragraph

In the June 27, 2006 Advisory Action, the Examiner stated that the rejection of claims 6, 9, 10, 12-15, 29, 31, 32 and 34-37 in the March 10, 2006 Final Office Action was maintained under 35 U.S.C. §112, second paragraph. Applicants understand this to refer to the rejection under 35 U.S.C. §112, first paragraph as set forth in the March 10, 2006 Final Office Action. Accordingly, claims 6, 9, 10, 12-15, 29, 31, 32 and 34-37 are rejected under 35 U.S.C. §112, first paragraph, as allegedly containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors had possession of the claimed invention at the time the application was filed.

In response, to advance prosecution of the subject application but without conceding the correctness of the Examiner's ground of rejection, applicants have cancelled claims 29, 31, 32, 34-36 and 52, and have deleted the recitation of treatment of thrombosis in claim 6. As amended, claims 6 and 29 instead recite treatment of a thrombotic disorder, wherein the thrombotic disorder is a thromboembolic disorder, an ischemic event, stroke, acute myocardial infarction, deep vein thrombosis, thrombophlebitis, or a cardiovascular disorder, support for each of which, and treatment thereof, may be found in the specification at, inter alia, page 5, lines 26-31, line 34 through page 6, line 8; and page 7, lines 9-11 and 27-32

Applicants maintain that the claimed subject matter is sufficiently described in the specification to meet the requirements of 35 U.S.C. §112, first paragraph.

If a telephone interview would be of assistance in advancing the

Michael J. Elliott et al. Applicants:

Serial No. : 08/602,272

Filed February 16, 1996

Page 6

prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee, other than the enclosed \$2,950.00 fee, including a \$2,160.00 fee for a five-month extension of time and \$790.00 fee for filing a Request for Continued Examination, is deemed necessary in connection with the filing of this Amendment and accompanying Request for Continued Examination. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box lexandria, VA 22313-1450

4/11/07

John P. White Date

Registration No. 28,678

Registration No. 28,678

Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 Tel. No. (212) 278-0400